D. Price (Aberdeen, United Kingdom), B. Stallberg (Trosa, Sweden)
Is pretreatment of a valved holding chamber (VHC) by priming with medication as effective as washing in ionic detergent?
J. P. Mitchell, M. W. Nagel, C. C. Doyle, V. I. Avvakoumova (London, Canada)
|  |
Severe asthmatic patients generate significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI)
K. Richter, B. Ellers-Lenz, T. D. Nguyen, U. Munzel, J. Maus, H. Magnussen (Großhansdorf, Offenbach, Frankfurt, Germany)
| |
What predicts short-acting beta agonist (SABA) monotherapy use in children?
L. Watson, P. G. Davey, P. W. James, K. F. Rabe (Greenford, Dundee, United Kingdom; Leiden, The Netherlands)
| |
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
P. Dorinsky, A. Emmett, L. Sutton (Research Triangle Park, United States Of America)
| |
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
P. Dorinsky, S. Yancey, D. Reilly, J. Stauffer, L. Edwards, L. Sutton (RTP, United States Of America)
| |
EXCEL: regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than with formoterol/budesonide combination (FBC)
R. Dahl, A. Chuchalin, A. Lindberg, M. Jones, S. K. Aggarwal, D. Gor (Arhus, Denmark; Moscow, Russia; Boden Lulea, Sweden; London, United Kingdom)
| |
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
R. M. Angus, A. A. Martin, R. F. Reagon (Liverpool, London, United Kingdom)
| |
²Stepping down[/quot] from fluticasone propionate/salmeterol 100/50mcg Diskus® results in loss of asthma control
P. Dorinsky, J. Stauffer, K. Waitkus-Edwards, S. Yancey, B. Prillaman, L. Sutton (Research Triangle Park, United States Of America)
| |
The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics
L. E. Adolfsson, S. Jern, D. Gor, C. Tyren (Bankeryd, Gothenburg, Molndal, Sweden; Greenford, United Kingdom)
| |
Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
P. Dorinsky, E. Kerwin, L. Schoaf, A. Ellsworth, K. House (Research Triangle Park, Medford, United States Of America)
| |
Clinical review of long-term pranlukast therapy in adult patients with bronchial asthma
K. Hirata, Y. Touda, H. Fujiwara, K. Komuta (Osaka, Osakasayama, Habikino, Japan)
| |
Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
F. S. F. Ram, F. M. Ducharme (London, United Kingdom; Montreal, Canada)
| |
Short course montelukast for intermittent asthma in children: economic analysis of the PRE-EMPT study
D. Price, C. F. Robertson, R. L. Henry, C. Mellis, D. Fitzgerald, N. Glasgow, A. Lee, J. Turner, M. Schulz, I. Noble (Aberdeen, United Kingdom; Melbourne, Sydney, Canberra, Australia)
| |
Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
K. Richter, P. Metzenauer, B. Ellers-Lenz, J. Maus, U. Petzold, H. Magnussen (Großhansdorf, Munich, Offenbach, Frankfurt, Germany)
| |
Budesonide/formoterol single inhaler therapy is well tolerated and reduces systemic steroid use
R. Scicchitano, M. Palmqvist, A. Andersson, K. Rabe (Adelaide, Australia; Gothenburg, Lund, Sweden; Leiden, The Netherlands)
| |
Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population
Y. Smorzik, Z. Yankova (Kfar Saba, Israel; Sofia, Bulgaria)
| |
Adjustable maintenance dosing (AMD) with budesonide/formoterol (B/F) meets guideline-defined management goals more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL)
R. Aalbers, T. Welte, C. Jorup (Groningen, The Netherlands; Magdeburg, Germany; Lund, Sweden)
| |
Budesonide/formoterol adjustable maintenance dosing (AMD) improves health-related quality of life (HRQL) compared with high-dose budesonide (AMD)
W. Pohl, N. Vetter, H. Zwick, W. Hrubos (Grimmenstein, Vienna, Austria)
| |
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens
E. Pizzichini, S. Romero, T. Ekström (Florianópolis, Brazil; Alicante, Spain; Lund, Sweden)
| |
Formoterol provides comparable bronchoprotection when delivered via DPI and MDI devices in mild-moderate asthmatics
E. J. Sims, A. H. Morice, B. J. O‘Connor, S. K. Das, B. J. Lipworth (Dundee, Hull, London, St Albans, United Kingdom)
| |